Co-Authors
This is a "connection" page, showing publications co-authored by THOMAS W BURKE and ROBERT COLEMAN.
Connection Strength
0.257
-
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. Gynecol Oncol. 2006 Apr; 101(1):126-31.
Score: 0.069
-
Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol. 1995 May; 57(2):215-20.
Score: 0.033
-
Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. Gynecol Oncol. 1994 Oct; 55(1):29-35.
Score: 0.032
-
Intraoperative radiographs to confirm the adequacy of lymph node resection in patients with suspicious lymphangiograms. Gynecol Oncol. 1993 Dec; 51(3):362-7.
Score: 0.030
-
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma. Int J Gynecol Cancer. 2011 Apr; 21(3):517-22.
Score: 0.025
-
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
Score: 0.024
-
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol. 2007 Jan; 104(1):100-3.
Score: 0.018
-
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 2002 Feb 01; 20(3):688-93.
Score: 0.013
-
Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. Gynecol Oncol. 2001 Nov; 83(2):276-81.
Score: 0.013